KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Treasury Shares (2018 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Treasury Shares data on record, last reported at $1.7 million in Q4 2025.

  • For Q4 2025, Treasury Shares fell 33.79% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, down 33.79%, while the annual FY2025 figure was $1.7 million, 33.79% down from the prior year.
  • Treasury Shares reached $1.7 million in Q4 2025 per AQST's latest filing, down from $2.9 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.3 million in Q2 2025 and bottomed at $8000.0 in Q2 2021.
  • Average Treasury Shares over 5 years is $1.2 million, with a median of $1.2 million recorded in 2024.
  • Peak YoY movement for Treasury Shares: plummeted 68.18% in 2021, then soared 2025.0% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $8000.0 in 2021, then surged by 1925.0% to $162000.0 in 2022, then soared by 722.22% to $1.3 million in 2023, then surged by 95.95% to $2.6 million in 2024, then tumbled by 33.79% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $1.7 million in Q4 2025, $2.9 million in Q3 2025, and $3.3 million in Q2 2025.